Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -43.56% is 41% above its 5-year average of -74.20%, near the high end of its 5-year range (-336.76%–-23.53%).
As of the fiscal period ended Tuesday, June 30, 2026. 26.63% above its 12-month average of -59.37%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -43.56%.
RETURN ON INVESTED CAPITAL (ROIC)
-43.56%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-59.37%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-98.87%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-74.20%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
+26.63%
CURRENT VS 3Y AVG
+55.94%
CURRENT VS 5Y AVG
+41.30%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-33.50%
median of 659 covered companies
CURRENT VS SECTOR MEDIAN
-30.03%
vs the sector median at left
Eupraxia Pharmaceuticals Inc.
Market Cap
$266.33M
Return on Invested Capital (ROIC)
-43.56%
TTM Avg
-59.37%
3Y Avg
-98.87%
5Y Avg
-74.20%
Market Cap
$266.79M
Return on Invested Capital (ROIC)
-15.00%
TTM Avg
-11.69%
3Y Avg
-3.29%
5Y Avg
-2.92%
Market Cap
$263.06M
Return on Invested Capital (ROIC)
-42.92%
TTM Avg
-30.10%
3Y Avg
-80.25%
5Y Avg
-64.52%
Market Cap
$265.80M
Return on Invested Capital (ROIC)
-39.76%
TTM Avg
-63.41%
3Y Avg
-63.96%
5Y Avg
-51.83%
Market Cap
$271.73M
Return on Invested Capital (ROIC)
-170.19%
TTM Avg
-56.97%
3Y Avg
-50.85%
5Y Avg
-45.83%
Market Cap
$262.11M
Return on Invested Capital (ROIC)
-28.96%
TTM Avg
-103.16%
3Y Avg
-110.30%
5Y Avg
-171.09%
Market Cap
$261.05M
Return on Invested Capital (ROIC)
-89.43%
TTM Avg
-77.88%
3Y Avg
-57.02%
5Y Avg
-48.01%
Market Cap
$257.42M
Return on Invested Capital (ROIC)
-3.17%
TTM Avg
-4.70%
3Y Avg
-2.14%
5Y Avg
-2.73%
Market Cap
$281.49M
Return on Invested Capital (ROIC)
-58.72%
TTM Avg
-52.25%
3Y Avg
-49.23%
5Y Avg
-41.07%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eupraxia Pharmaceuticals Inc. (EPRX) | $266.33M | -43.56% | -59.37% | -98.87% | -74.20% |
| OraSure Technologies, Inc. (OSUR)vs › | $266.79M | -15.00% | -11.69% | -3.29% | -2.92% |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $263.06M | -42.92% | -30.10% | -80.25% | -64.52% |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $265.80M | -39.76% | -63.41% | -63.96% | -51.83% |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $271.73M | -170.19% | -56.97% | -50.85% | -45.83% |
| Palisade Bio, Inc. (PALI)vs › | $262.11M | -28.96% | -103.16% | -110.30% | -171.09% |
| AC Immune S.A. (ACIU)vs › | $261.05M | -89.43% | -77.88% | -57.02% | -48.01% |
| Anika Therapeutics, Inc. (ANIK)vs › | $257.42M | -3.17% | -4.70% | -2.14% | -2.73% |
| Fate Therapeutics, Inc. (FATE)vs › | $281.49M | -58.72% | -52.25% | -49.23% | -41.07% |
| Century Therapeutics, Inc. (IPSC)vs › | $256.22M | -43.69% | -34.60% | -35.16% | -35.84% |
ROIC
-43.6%
ROE
-38.3%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -43.56% |
| 2026-03-31 | -34.25% |
| 2025-12-31 | -47.73% |
| 2025-09-30 | -33.37% |
| 2025-06-30 | -137.92% |
| 2025-03-31 | -100.70% |
| 2024-12-31 | -78.61% |
| 2024-09-30 | -336.76% |
| 2024-06-30 | -151.49% |
| 2024-03-31 | -122.44% |
| 2023-12-31 | -265.79% |
| 2023-09-30 | -70.16% |
| 2023-06-30 | -100.40% |
| 2023-03-31 | -100.31% |
| 2022-12-31 | -82.97% |
| 2022-09-30 | -65.64% |
| 2022-06-30 | -55.16% |
| 2022-03-31 | -61.73% |
| 2021-12-31 | -57.95% |
| 2021-09-30 | -41.88% |
| 2021-06-30 | -23.53% |
| 2021-03-31 | -16.27% |
